NCT06904573View on ClinicalTrials.gov

Probiotics in Advanced Urothelial Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

222

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2028

Conditions
Advanced Urothelial CarcinomaProbioticsImmunotherapy
Interventions
DRUG

Probiotics Compound (Biolosion)

15g, PO, qd

DRUG

Nab-paclitaxel

230mg/m2, IV, days 1, 8, q3w

DRUG

Cisplatin

70mg/m2, IV, days 1-3, q3w

DRUG

Gemcitabine

1.2g/m2, IV, days 1, 8, q3w

DRUG

Disitamab vedotin

2.5mg/kg, IV, q2w

DRUG

Enfortumab Vedotin

1.25mg/kg, IV, days 1, 8, q3w

DRUG

Pembrolizumab

200mg, IV, q3w

DRUG

Toripalimab

240mg, IV, q3w

Trial Locations (3)

510000

RECRUITING

Sun yat-sen university cancer center, Guangzhou

Unknown

NOT_YET_RECRUITING

Sun Yat-sen Memorial Hospital, Guangzhou

NOT_YET_RECRUITING

Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan

All Listed Sponsors
lead

Sun Yat-sen University

OTHER